Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Paul Schimmel sold 27,823 shares of the business’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $150.00, for a total transaction of $4,173,450.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $1,500,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $141.38 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a market cap of $13,900.00, a PE ratio of -26.13 and a beta of 2.67. Alnylam Pharmaceuticals, Inc. has a one year low of $46.90 and a one year high of $152.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). The firm had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The company’s revenue for the quarter was up 116.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.32) earnings per share. equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.
ALNY has been the subject of a number of recent research reports. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Sunday, January 7th. B. Riley reaffirmed a “buy” rating and set a $205.00 price objective (down previously from $220.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. Nomura boosted their price objective on shares of Alnylam Pharmaceuticals to $86.00 and gave the company a “sell” rating in a research report on Friday, February 9th. Finally, Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $126.89.
Large investors have recently modified their holdings of the company. Strs Ohio acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $141,000. CENTRAL TRUST Co lifted its stake in shares of Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $165,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $235,000. Finally, American International Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $255,000. 92.44% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/16/paul-schimmel-sells-27823-shares-of-alnylam-pharmaceuticals-inc-alny-stock.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.